台万一
职称/职务：教授
通讯地址：湖北省武汉市武昌区东湖路185号金沙集团wwW3354CC
办公地址：武汉大学医学部8号楼905室
办公电话：
课题组网站：http://wytai.whu.edu.cn
学习简历：
2000.09 - 2004.07 中国药科大学，中药药剂学学士
2004.09 - 2007.07 中国科学院上海药物研究所，药物化学硕士
2007.08 - 2012.08 美国密苏里大学堪萨斯城分校，药剂学博士
工作简历：
2012.09 - 2013.11 美国北卡罗来纳大学教堂山分校生物医学工程系，博士后
2013.12 - 2018.12 美国华盛顿大学生物工程系，博士后
2019.02 – 2020.11 金沙集团wwW3354CC，特聘研究员
2020.12 -现在 金沙集团wwW3354CC，教授
研究领域
药剂学、抗体工程、生物大分子药物递送
研究兴趣与方向
● siRNA的化学修饰与递送
利用化学修饰和生物偶联技术，提高siRNA的靶向性、疏水性、体内稳定性和生物相容性。设计新型脂质分子、siRNA复合蛋白和嵌合受体，发展靶向性的脂质体、外泌体等膜囊类siRNA递送载体。
● 融合蛋白，融合抗体的结构设计以及药物偶联技术开发
抗体和蛋白质的功能和结构具有模块化特点，利用生物合成和蛋白质重组技术，对抗体或者其它治疗性蛋白质进行结构设计和功能模块重搭建，实现靶向、载药、变构、双特异性和多功能融合，以获得可精准调控的新型抗体药物和抗体类药物载体。
代表性论文：
1. Yan Zheng, Wanyi Tai*. “Insight into the siRNA transmembrane delivery — from cholesterol conjugating to tagging.” WIREs Nanomed. Nanobiotechnol. 2019, e1606
2. Wanyi Tai*. Current aspects of siRNA bioconjugate for in vitro and in vivo delivery. Molecules 2019, 24(12), 2211
3. Wanyi Tai*. Chemical Modulation of siRNA lipophilicity for efficient delivery. Journal of Controlled Release 2019, 307, 98-107.
4. Wanyi Tai#, Pengfei Zhao#, Xiaohu Gao*. Cytosolic delivery of proteins by cholesterol tagging. Sci. Adv. 2020, 6, abb0310
5. Wanyi Tai, Xiaohu Gao*. Silencing ribonucleoprotein: a biomimetic platform for targeted siRNA delivery. Advanced Functional Materials 2019, 29, 1902221
6. Wanyi Tai, Xiaohu Gao*. Synthetic polymer tag for intracellular delivery of siRNA. Advanced Biosystems 2018, 2. 1800075
7. Wanyi Tai, Junwei Li, Eva Corey, Xiaohu Gao*. A ribonucleoprotein octamer for targeted siRNA delivery. Nature Biomedical Engineering 2018, 2(5), 326-337
8. Wanyi Tai, Xiaohu Gao*. Noncovalent tagging of siRNA with steroids for transmembrane delivery. Biomaterials 2018, 178. 720-727.
9. Wanyi Tai, Xiaohu Gao*. Functional peptides for siRNA delivery Advanced Drug Delivery Reviews 2017, 110–111, 157–168.
10. Wanyi Tai, Ran Mo, Jin Di, Vinayak Subramanian, Xiao Gu, Zhen Gu*. Bio-inspired nanovesicles for glucose-responsive release of insulin. Biomacromolecules 2014, 15(10), 3495-3502.
11. Wanyi Tai#, Ran Mo#, Yue Lu, Tianyue Jiang, Zhen Gu*. Folding graft copolymer with pendant drug segment for co-delivery of anticancer drugs. Biomaterials 2014, 35(25), 7194-7203.
12. Wanyi Tai, Zhijin Chen, Ashutosh Barve, Zhonghua Peng, Kun Cheng*. A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer. Pharmaceutical Research 2014, 31(3), 706-719
13. Wanyi Tai, Zhijin Chen, Kun Cheng*. Expression profile and functional activity of peptide transporters in prostate cancer cells. Molecular Pharmaceutics 2013, 10(2), 477-487
14. Wanyi Tai, Ravi S. Shukla, Bin Qin, Benyi Li, Kun Cheng*. Development of a peptide-drug conjugate for prostate cancer therapy. Molecular Pharmaceutics 2011, 8(3), 901-912
15. Wan-Yi Tai#, Run-Tao Zhang#, Yi-Ming Ma, Min Gu, Gang Liu, Jia Li, Fa-Jun Nan*. Design, synthesis, and biological evaluation of ring‐opened bengamide analogues. ChemMedChem 2011, 6(9), 1555-1558.
16. Wanyi Tai, Rubi Mahato, Kun Cheng*. The role of HER2 in cancer therapy and targeted drug delivery. Journal of Controlled Release 2010, 146(3), 264-275
17. Wanyi Tai, Bin Qin, Kun Cheng*. Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF. Molecular Pharmaceutics 2010, 7(2), 543-556
18. Gang Liu#, Yi-Ming Ma#, Wan-Yi Tai#, Chuan-Ming Xie, Yu-Lin Li, Jia Li and Fa-Jun Nan*. 2008, Design, synthesis, and biological evaluation of caprolactam-modified bengamide analogues. ChemMedChem 2008, 3(1), 74–78.
发表著作
1.Wanyi Tai, Zhen Gu*. Chapter 16 “Methods of folding a graft copolymer with dual anticancer drug and related applications” In Peter Grunwald edits “Biocatalysis & Nanotechnology” (2017), Pan Stanford Publishing Pte. Ltd.
2.Wanyi Tai, Kun Cheng*. Chapter 17 “Advanced drug delivery in cancer therapy” In Mitra AK, Lee C. Cheng K. edits “Advanced drug delivery” (2013), Wiley-Blackwell, John Wiley & Sons, Inc.
欢迎相关专业博士后、研究生、本科生加入本课题组。
